Annie Wong-Beringer
Annie Wong-Beringer
Verified email at
Cited by
Cited by
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity
LK Hidayat, DI Hsu, R Quist, KA Shriner, A Wong-Beringer
Archives of internal medicine 166 (19), 2138-2144, 2006
Lipid formulations of amphotericin B: clinical efficacy and toxicities
A Wong-Beringer, RA Jacobs, BJ Guglielmo
Clinical Infectious Diseases 27 (3), 603-618, 1998
Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the …
MJ Rybak, J Le, TP Lodise, DP Levine, JS Bradley, C Liu, BA Mueller, ...
Clinical Infectious Diseases 71 (6), 1361-1364, 2020
Regulatory oversight and safety of probiotic use
V Venugopalan, KA Shriner, A Wong-Beringer
Emerging infectious diseases 16 (11), 1661, 2010
Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus …
DI Hsu, LK Hidayat, R Quist, J Hindler, A Karlsson, A Yusof, ...
International journal of antimicrobial agents 32 (5), 378-385, 2008
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy
A Wong-Beringer, J Joo, E Tse, P Beringer
International journal of antimicrobial agents 37 (2), 95-101, 2011
Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa
J Kriengkauykiat, E Porter, O Lomovskaya, A Wong-Beringer
Antimicrobial agents and chemotherapy 49 (2), 565-570, 2005
Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae with Reduced Susceptibility …
A Wong-Beringer, J Hindler, M Loeloff, AM Queenan, N Lee, DA Pegues, ...
Clinical Infectious Diseases 34 (2), 135-146, 2002
Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients
E Minejima, J Choi, P Beringer, M Lou, E Tse, A Wong-Beringer
Antimicrobial agents and chemotherapy 55 (7), 3278-3283, 2011
Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes
DI Hsu, MP Okamoto, R Murthy, A Wong-Beringer
Journal of Antimicrobial Chemotherapy 55 (4), 535-541, 2005
Comparison of type III secretion system virulence among fluoroquinolone-susceptible and-resistant clinical isolates of Pseudomonas aeruginosa
A Wong-Beringer, J Wiener-Kronish, S Lynch, J Flanagan
Clinical Microbiology and Infection 14 (4), 330-336, 2008
Therapeutic Challenges Associated with Extended‐Spectrum, β‐Lactamase‐Producing Escherichia coli and Klebsiella pneumoniae
A Wong‐Beringer
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (5 …, 2001
Economic aspects of antibacterial adverse effects
PM Beringer, A Wong-Beringer, JP Rho
Pharmacoeconomics 13 (1), 35-49, 1998
Systemic antifungal therapy: new options, new challenges
A Wong‐Beringer, J Kriengkauykiat
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 23 (11 …, 2003
Immune globulin therapy in allogeneic bone marrow transplant: a critical review.
BJ Guglielmo, A Wong-Beringer, CA Linker
Bone marrow transplantation 13 (5), 499-510, 1994
Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa
M Agnello, A Wong-Beringer
PloS one 7 (8), e42973, 2012
A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients
DI Hsu, M Nguyen, L Nguyen, A Law, A Wong-Beringer
Journal of antimicrobial chemotherapy 65 (8), 1765-1770, 2010
Treatment of funguria
A Wong-Beringer, RA Jacobs, BJ Guglielmo
Jama 267 (20), 2780-2785, 1992
Influence of timing of antibiotic administration on tissue concentrations during surgery
A Wong-Beringer, RL Corelli, TR Schrock, BJ Guglielmo
The American journal of surgery 169 (4), 379-381, 1995
Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates
RM Humphries, JA Hindler, A Wong-Beringer, SA Miller
Antimicrobial agents and chemotherapy 61 (12), e01858-17, 2017
The system can't perform the operation now. Try again later.
Articles 1–20